Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?
Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.
Endocrinology Advisor15h
Baqsimi Approved for Severe Hypoglycemia Treatment in Younger Patients
The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.